Table 1. Summary of genomic alterations in late passage H460 TDECs.
| Chromosomal Position &Alteration | Gain/Del | Possible Genes Affected | GenBank Accession Number | Location of Alteration Relative to Altered Gene | Proposed Biological Role(s) | Refs. |
| 2p16.3 (50,190,353-50,381,744) | Gain | NRXN1 | AB011150 | Exons 20-22 | nervous and vascular systems | 23 |
| 2q22.1 (142,210,528-142,468,442) | Del | LRP1B | NM_018557 | Exon 3 | deleted in cancers | 24 |
| 3q13.31/32 (117,059,636-117,473,977) | Del | LSAMP | NM_002338 | 5′ | tumor suppressor, VEGFR1 regulator | 25 |
| LSAMP-AS3 | 5′ | noncoding LSAMP antisense RNA | 25 | |||
| LSAMP-AS4 | 5′ | noncoding LSAMP antisense RNA | 25 | |||
| 3q26.31 (173,271,684-173,472,327) | Del | NLGN1 | NM_014932 | Exons 1b-2 | nervous and vascular systems | 23 |
| 4q34.3 (182,009,132-182,158,533) | Del | LINC00290 | Intergenic | |||
| 5q11.2 (58,349,882-58,730,285) | Del | PDE4D | NM_001104631 | Exons 2–5 | promotes survival, proliferation, EMT | 26 |
| RAB3C | NM_138453 | 3′ | exocytosis regulation | 27 | ||
| PART1 | NR_024617 | 5′ | (long non-coding RNA) | |||
| DEPDC1B | NM_018369 | 5′ | deleted in sporadic breast cancer | 28 | ||
| ELOVL7 | NM_024930 | 5′ | LCFA elongase, prostate cancer | 29 | ||
| ERCC8 | NM_000082 | 5′ | DNA repair | 30 | ||
| 5q34 (164,826,163-165,260,961) | Del | ODZ2 | AB032953 | 5′ | a transmembrane protein predominantly expressed in nervous system; deregulatedin lymphoma | 31,32 |
| 9p21.1 (28,378,229-28,587,832) | Del | LINGO2 | AL353746 | Exon 2 | transmembrane protein, typicallyexpressed early in development | 33 |
| 13q33.3 (107,685,848-107,885,801) | Gain | FAM155A | L10374 | Exons 2–3 | unknown | |
| ARGLU1 | BC071587 | 3′ | required for estrogen-dependentgene transcription and breast cancer cell growth | 34 | ||
| EFNB2 | NM_004093 | 3′ | angiogenesis | 35 | ||
| LIG4 | NM_002312 | 5′ | DNA repair | 36 | ||
| 14q (entire chromosome) | Loss | All | - | - | ||
| 20p12.1 (14,858,910-14,914,578) | Del | MACROD2 | NM_080676 | Intron 5 | An O-acetyl-ADP-ribose deacetylase;deleted in colorectal cancer | 37,38 |
The nucleotide coordinates of genomic alterations in SP5 and SP6 TDECs were determined by the first and last SNPs that differed from those of early passage TDECs and the precise locations were obtained using the Ensembl Genome Browser 57 database.